News
TipRanks on MSN16h
BioNTech’s Phase II Study on BNT327: A Potential Game-Changer in Lung Cancer Treatment
The study tests BNT327, an investigational drug administered via intravenous infusion, in combination with standard chemotherapy drugs like etoposide, carboplatin, paclitaxel, and topotecan. The goal ...
TipRanks on MSN1d
BioNTech’s BNT327 Trial: A New Hope for Small-cell Lung Cancer?
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
In August 2025, BioNTech SE organized a Phase II study in participants with untreated extended-stage small-cell lung cancer (ES-SCLC) (Cohort 1) or small-cell lung cancer (SCLC) which has progressed ...
The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.
The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.
The gush of second quarter earnings reports is beginning to slow to a trickle, and with most of the reports in, the results have been mostly positive.
Get the latest Bristol-Myers Squibb Company (BMY) stock news and headlines to help you in your trading and investing decisions.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback